Carla Zeballos Torrez
Assistant Professor of Radiology at the Hospital of the University of Pennsylvania
Moonlighter, Breast Imaging, Hospital of the University of Pennsylvania
Active Medical Staff, Penn Presbyterian Medical Center, Department of Radiology, Division of Breast Imaging
Active Medical Staff, Chester County Hospital, Department of Radiology, Division of Breast Imaging
Active Medical Staff, Pennsylvania Hospital, Department of Radiology, Division of Breast Imaging
Attending, Hospital of the University of Pennsylvania, Department of Radiology, Division of Breast Imaging
Department: Radiology
Contact information
Department of Radiology
Hospital of the University of Pennsylvania
3400 Spruce Street, One Silverstein Building
Philadelphia, PA 19104
Hospital of the University of Pennsylvania
3400 Spruce Street, One Silverstein Building
Philadelphia, PA 19104
Education:
BA
University of Virginia, 2008.
MD
Drexel University College of Medicine, 2013.
PhD (Cancer Biology)
University of Texas Health San Antonio, 2019.
Permanent linkBA
University of Virginia, 2008.
MD
Drexel University College of Medicine, 2013.
PhD (Cancer Biology)
University of Texas Health San Antonio, 2019.
Selected Publications
Zheng G, Wu L, Bouamar H, Cserhati M, Chiu YC, Hinck CS, Wieteska Ł, Zeballos Torrez CR, Hu R, Easley A, Chen Y, Hinck AP, Cigarroa FG, Sun LZ: Ficolin-3 induces apoptosis and suppresses malignant property of hepatocellular carcinoma cells via the complement pathway. Life Sci 357: 123103, Nov 2024 Notes: doi: 10.1016/j.lfs.2024.123103. Epub 2024 Sep 30.Chahine C, Dai M, Torrez CZ, Whorms D, Oliva C, Smith T, Suresh K, Shuda J, Nunes LW: Bridging the gap – early community outreach as an initiative to increase representation in radiology. Acad Radiol Oct 2024 Notes: Epub ahead of print. DOI: 10.1016/j.acra.2024.09.055.
Zeballos Torrez C, Easley A, Bouamar H, Zheng G, Gu X, Yang J, Chiu YC, Chen Y, Halff GA, Cigarroa FG, Sun LZ: STEAP2 promotes hepatocellular carcinoma progression via increased copper levels and stress-activated MAP kinase activity. Sci Rep 14(1): 12753, Jun 2024.
C Zeballos Torrez*, A Chen*, L Peterson, M Muzi, J Specht, H Linden, E Cohen, D Kontos, D Mankoff: Novel 4D radiomics applied to dynamic FES PET images to improve prediction of breast cancer response to ER-targeted Therapy. 2024 San Antonio Breast Cancer Symposium 2024 Notes: Selected for a Spotlight Poster Discussion.
Das D, Wang X, Chiu YC, Bouamar H, Sharkey FE, Lopera JE, Lai Z, Weintraub ST, Han X, Zou Y, Chen HH, Zeballos Torrez CR, Gu X, Cserhati M, Michalek JE, Halff GA, Chen Y, Zheng S, Cigarroa FG, Sun LZ: Integrative multi-omics characterization of hepatocellular carcinoma in hispanic patients. J Natl Cancer Inst 2024 Notes: Epub ahead of print. DOI: 10.1093/jnci/djae207.
Ginzberg SP, Edmonds CE, Dako F, Donnell T, Washington AL, Elmore LC, Lee DJ, Vachani A, Mincarelli D, Zeballos Torrez C, McCormick TM, Rodriguez V, Nguyen V, Oliva C, Atherholt B, Gaiser R, Congiu L, Grant B, Gungor M, Englander BS, Guerra CE, Nunes LW: Together We Go Farther: Improving Access to Cancer Screening Through a Multidisciplinary, One-Stop-Shop Approach. Acad Radiol 30(12): 3153-3161, Dec 2023.
Zeballos Torrez CR, Gasior JA, Ginzberg SP, Nunes LW, Fayanju OM, Englander BS, Elmore LC, Edmonds CE: Identifying and Addressing Barriers to Screening Mammography in a Medically Underserved Community. Acad Radiol 31(7): 2643-2650, Jul 2023.
C Zeballos Torrez, J Gasior, L Nunes, O Fayanju, B Englander, L Elmore, C Edmonds: Identifying and addressing barriers to screening mammography in a medically underserved community. Journal of Clinical Oncology 41: e18685-e18685, May 2023.
Zheng G, Bouamar H, Cserhati M, Zeballos CR, Mehta I, Zare H, Broome L, Hu R, Lai Z, Chen Y, Sharkey FE, Rani M, Halff GA, Cigarroa FG, Sun LZ: Integrin alpha 6 is upregulated and drives hepatocellular carcinoma progression through integrin α6β4 complex. Int J Cancer 151(6): 930-943, Sep 2022.
Xia L, Bouamar H, Gu X, Zeballos C, Qin T, Wang B, Zhou Y, Wang Y, Yang J, Zhu H, Zhang W, Houghton PJ, Sun LZ: Gli2 mediates the development of castration‑resistant prostate cancer. Int J Oncol 57(1): 100-112, Jul 2020.